マイアミオープンフェデラー

MENU Company Company Back Company Message from Top Management Our Founding Spirit Brand Statement Our Story Our History of Value Creation Vision and Strategy Framework Group Vision Long-Term Management Strategy Management Policy Medium-Term Management Plan Corporate Information and Business Sites Business Overview Introduction of Executives Corporate Governance Group Companies Procurement Policy Corporate Policy over Internal Control Integrated Report Products and Technology Products Back Products Search by Application Mobility Architectural Materials Infrastructure / General Industry Electronics Semiconductors Energy Daily commodities, Food industry Life Science Search by Business Category Architectural Glass Automotive Display Electronic Materials Essential Chemicals Performance Chemicals Life Science Ceramics New Business Search by Name Search by Keyword Technology and Innovation back Technology and Innovation A Message from the Chief Technology Officer Technology Development Strategy Intellectual Property Strategy R&D Structure Core Technologies Technology Highlights Mobility Electronics Life Science AGC Yokohama Technical Center AGC OPEN SQUARE “AO” Overview Facility Guide Access Collaboration Research Collaboration System R&D Library Measures to Prevent Misconduct in Research and Properly Manage Public Research Funds Sustainability Sustainability Back Sustainability Protecting the Global Environment and Utilizing Resources Supporting the Evolution of Cities and Mobility Realizing Longevity Society Where People Can Live in Good Health Creating a Healthy and Secure Society through Connections Generating New Value from Fair and Safe Workplaces Message from the President and CEO The AGC Group’s Sustainability Management Sustainability Promotion System Download Report Site Reports External Evaluations GRI Standards Index Sustainability-related policies, criteria, and guidelines AGC Group Code of Conduct/Compliance Help Lines Investors Investors Back Investors Management Information To Our Shareholders Vision and Strategy Framework Business Risks Disclosure Policy Financial Highlights IR News IR Library Company Overview Presentations of Financial Results Presentations of Business Briefings Financial Results Financial Review AGC Review (Newsletter for Shareholders) ESG Information Sustainability Corporate Governance Integrated Report Stock and Bond Information Stock Information Corporate Bond and Rating Information Dividend Information Analyst Coverage General Meeting of Shareholders Methods for Various Stock Procedures Electronic Public Notice Articles of Incorporation Stock Price Contact Us FAQ IR Email News Support Information IR Calendar Cautionary Statement IR Site Map Careers News Contact EN JP CN Search November 17, 2020Management Download PDF Print AGC Biologics to Expand Biopharmaceutical CDMO Capacity Doubling the production capacity at its site in Denmark to address strong demand AGC (Headquarters: Tokyo; President: Takuya Shimamura) has announced that AGC has decided to increase the production capacity of its biopharmaceutical CDMO*1 subsidiary, AGC Biologics (Headquarters: United States). AGC Biologics will construct a new building on land adjacent to its current Copenhagen site, adding production floors with 2,000L single-use bioreactors*2, labs and office space. The total investment for this expansion is estimated to be around 20 billion JPY, and the start of operation is scheduled for 2023. The biopharmaceutical CDMO market continues to grow at around 10% annually, and the accumulation of contracts awarded to AGC Biologics is outpacing the market. This expansion will more than double AGC Biologics’ single-use bioreactor mammalian cell-culture capacity in Copenhagen, enabling AGC Biologics to meet the needs of the market. The new building will have a total floor area of approximately 19,000㎡ supporting continued growth. Under AGC plus management policy, AGC Group has positioned its Life Science business including its biopharmaceutical CDMO services, as one of its strategic businesses. The Group has been expanding its Life Science business through multiple acquisitions and capital investments in biopharmaceutical services using mammalian cells and microorganisms, as well as in synthetic pharmaceutical and agrochemical services. Most recently, in July 2020, AGC expanded the scope of CDMO services into the rapidly growing gene and cell therapy fields through the acquisition of Molmed S,p.A (now AGC Biologics S.p.A.). AGC’s Life Science business is expecting to achieve its initial 2025 sales target of 100 billion yen, two to three years ahead of its original plan. AGC continues to strive to be a company that actively contributes to the pharmaceutical companies, patients, and the wider society as a whole. Notes: *1 CDMO: Contract Development & Manufacturing Organization. A company which is contracted on behalf of another company to serve product manufacturing as well as the development of manufacturing processes. *2 Single-use: Bioreactors that use disposable culture vessels ■AGC Group’s CDMO Business Sites MEDIA INQUIRIES Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations DivisionAGC Inc. Contact: Tomoko Nakao TEL: +81-3-3218-5603 E-mail: [email protected] Share News Index HomeNewsAGC Biologics to Expand Biopharmaceutical CDMO Capacity Check in AGC Site Map About Social Media Contact About This Site Privacy Policy ©AGC Inc.